BiotechTube
Judo Bio

Judo Bio

San Diego, United States· Est.
judo.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Judo Bio is an early-stage biotech focused on overcoming the historical challenge of delivering genetic medicines to the kidney. Its core innovation is the STRIKE platform, which harnesses endogenous renal recycling receptors, like megalin, for cell-specific delivery of siRNA therapeutics. The company is building a preclinical pipeline targeting solute carrier proteins and other disease-modifying genes, aiming to treat both kidney-specific and systemic conditions. Led by a team with deep experience in oligonucleotide drug development, Judo Bio is positioned to explore a significant unmet medical need in a previously 'undruggable' organ.

Renal DiseasesSystemic Diseases

Technology Platform

STRIKE (Selectively Targeting RNA Into KidnEy) platform: A proprietary approach using ligand-siRNA conjugates designed to bind to endogenous recycling receptors (e.g., megalin) in the kidney for cell-type-specific delivery and gene silencing.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The kidney represents a vast, underserved therapeutic area with high unmet need across chronic, rare, and systemic diseases.
Successfully proving targeted oligonucleotide delivery could establish a new modality, creating a first-mover advantage in a potential multi-billion dollar market.
The platform's applicability to both renal-specific and systemic indications broadens the potential addressable patient population.

Risk Factors

The core technology is unproven in humans, facing risks related to delivery efficiency, potency, and safety.
The platform's initial reliance on megalin may limit its reach to certain kidney cell types.
The company faces competition from larger biopharma firms increasingly interested in renal targets and the challenges of developing and commercializing therapies for rare diseases.

Competitive Landscape

The competitive landscape for kidney-targeted RNAi is emerging but not yet crowded. Judo Bio's primary competition comes from larger RNAi leaders like Alnylam and Arrowhead Pharmaceuticals, who have advanced liver-targeted platforms and may expand to other tissues. Other biotechs are exploring alternative kidney delivery technologies (e.g., peptides, novel conjugates). Judo's focused platform and experienced team provide a differentiated, specialized approach.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →